EEF1A1P30: A Potential Drug Target and Biomarker (G402420)

Target Name: EEF1A1P30

NCBI ID: G402420

EEF1A1P30

Other Name(s): Eukaryotic translation elongation factor 1 alpha 1 pseudogene 30 | eukaryotic translation elongation factor 1 alpha 1 pseudogene 30

EEF1A1P30: A Potential Drug Target and Biomarker

The protein encoded by the EEF1A1P30 gene is a member of the family of translation elongation factors, which are essential for the process of translation of mRNAs into proteins. Mutations in the EEF1A1P30 gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases , and developmental disorders. As a result, EEF1A1P30 has emerged as a promising drug target and biomarker for a variety of diseases.

The EEF1A1P30 gene is located on chromosome 19q31 and encodes a protein of 21 kDa. The protein is composed of 215 amino acid residues and has a calculated pI of 5.95. The protein is expressed in most tissues and cells of the body and is involved in the process of translation elongation, which is the final step in the process of protein synthesis.

Mutations in the EEF1A1P30 gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that mutations in the EEF1A1P30 gene are associated with an increased risk of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, mutations in the EEF1A1P30 gene have also been linked to an increased risk of cancer, including breast and ovarian cancers.

As a result of these associations, EEF1A1P30 has emerged as a promising drug target and biomarker for a variety of diseases. One potential approach to targeting EEF1A1P30 is to use small molecules or antibodies that can interact with the protein and prevent it from functioning correctly. This could lead to the development of drugs that can treat diseases associated with dysfunctional EEF1A1P30, such as cancer and neurodegenerative diseases.

Another approach to targeting EEF1A1P30 is to use genetic modifiers that can alter the expression or activity of the protein. For example, researchers have used CRISPR/Cas9 technology to modify the expression of the EEF1A1P30 gene in cancer cells. By introducing mutations or other genetic changes into the gene, researchers have been able to reduce the expression of the protein and reduce the risk of cancer.

In addition to its potential as a drug target and biomarker, EEF1A1P30 also has potential as a diagnostic tool. The protein is expressed in most tissues and cells of the body, which makes it a potential target for diagnostic techniques such as Western blotting or immunofluorescence. By using these techniques, researchers can detect the expression of EEF1A1P30 in a variety of tissues and cells and quantify it using techniques such as ELISA or western blot.

Overall, EEF1A1P30 is a promising drug target and biomarker for a variety of diseases. Its function as a protein involved in translation elongation makes it an attractive target for small molecules or antibodies that can prevent it from functioning correctly. Additionally, its potential as a diagnostic tool adds to its appeal as a potential drug. Further research is needed to fully understand the function of EEF1A1P30 and its potential as a drug target and biomarker.

Protein Name: Eukaryotic Translation Elongation Factor 1 Alpha 1 Pseudogene 30

The "EEF1A1P30 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1A1P30 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets